The Patent Finder

Composition and Method for Treating Neurological Disease (2005)

Adamas Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,389,578Composition and Method for Treating Neurological Disease
In force
 · High confidence
UsedRemaining
Adamas Pharmaceuticals, Inc.In forceHigh confidence
US 8,796,337Composition and Method for Treating Neurological Disease
Term ended · USPTO later recorded non-payment Sep 7, 2026
Term ended Nov 23, 2025 · High confidence
Adamas Pharmaceuticals, Inc.Term ended
USPTO later recorded non-payment Sep 7, 2026
Term ended Nov 23, 2025High confidence
US 8,889,740Composition and Method for Treating Neurological Disease
Term ended
Ended no later than Nov 23, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 23, 2025Medium confidence
US 8,895,614Composition and Method for Treating Neurological Disease
Term ended
Ended no later than Nov 23, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 23, 2025Medium confidence
US 8,895,615Composition and Method for Treating Neurological Disease
Term ended
Ended no later than Nov 23, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 23, 2025Medium confidence
US 8,895,616Composition and Method for Treating Neurological Disease
Term ended
Term ended Nov 23, 2025 · High confidence
Adamas Pharmaceuticals, Inc.Term endedTerm ended Nov 23, 2025High confidence
US 8,895,617Composition and Method for Treating Neurological Disease
Term ended
Ended no later than Nov 23, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 23, 2025Medium confidence
US 8,895,618Composition and Method for Treating Neurological Disease
Term ended
Ended no later than Nov 23, 2025 · Low confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 23, 2025Low confidence
US 8,987,333Composition and Method for Treating Neurological Disease
Term ended
Ended no later than Nov 23, 2025 · Low confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 23, 2025Low confidence
US 9,072,697Composition and Method for Treating Neurological Disease
Term ended
Term ended Nov 23, 2025 · Low confidence
Adamas Pharmaceuticals, Inc.Term endedTerm ended Nov 23, 2025Low confidence
9 more records in this group · Pro
10 of 19 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 19, including 9 expired and 1 expiring within the 18 months from Nov 21, 2026.
Upgrade to Pro
1 of these is in force and held by Adamas Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited